Nectin Therapeutics
PrivateLast Round
VC Round
May 6, 2024
Total Funding Raised
$11.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nectin Therapeutics is a biotechnology company that develops next-generation immuno-oncology therapies and antibody-drug conjugates to treat solid and hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nectin Therapeutics Comparables
Compare Nectin Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 73% | |
| iTeos Therapeutics | 73% | |
| Compugen Ltd. | 71% |
Nectin Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 6, 2024 | ||||
| VC Round | May 16, 2023 | ||||
| Grant | Nov 30, 2022 | ||||
| VC Round | Mar 7, 2022 | ||||
| Series A | Jul 14, 2020 |
Key People
Founding team and executive leadership
Nectin Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Biotech Fund | VC Round, Grant |
| Peregrine Ventures (California) | Grant |
| The University of Texas MD Anderson Cancer Center | Grant |
| Integra Holdings | Series A, VC Round, Grant |
| aMoon | Grant |
| Cancer Focus Fund | VC Round, Grant |
| Guangzhou Sino-Israel Bio-Industry Investment Fund | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 68% MoM, reaching 2.4K.
- Nov 30, 2022
$5.4M grant round led by Israel Biotech Fund.
Nectin Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nectin Therapeutics's valuation, stock price, and market status.
Is Nectin Therapeutics a public or private company?
Nectin Therapeutics is a private company.
What is the current stock price of Nectin Therapeutics?
Nectin Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Nectin Therapeutics worth (valuation)?
Valuation information for Nectin Therapeutics is not publicly available.
Can I buy Nectin Therapeutics stock?
Nectin Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nectin Therapeutics's last funding round?
Nectin Therapeutics's most recent funding round was Series A on May 6, 2024.
Who are the main investors in Nectin Therapeutics?
Key investors in Nectin Therapeutics include Israel Biotech Fund, Cancer Focus Fund.
Will Nectin Therapeutics IPO soon?
No public IPO plans have been announced for Nectin Therapeutics.
How can I track Nectin Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nectin Therapeutics's secondary market activity and sign up for updates.